AZD2423 Safety and Tolerability Study in patients with moderate and severe Chronic Obstructive Pulmonary Disease(COPD)

Study identifier:D3320C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients with Moderate to Severe COPD

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD2423, Placebo to AZD2423

Sex

All

Actual Enrollment

63

Study type

Interventional

Age

40 Years - 80 Years

Date

Study Start Date: 01 Oct 2010
Primary Completion Date: 01 Mar 2011
Study Completion Date: 01 Mar 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Oct 2014 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria